Intra-Cellular Therapies, Inc. (ITCI) has a consensus analyst rating of Buy, based on 23 analysts covering the stock. Of those, 14 recommend buying, 9 recommend holding, and 0 recommend selling.
The analyst consensus price target for ITCI is $132.00, representing a +0.1% upside from the current price of $131.87. Price targets range from a low of $132.00 to a high of $132.00.
